Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial.

Date publication

juin 2020

Journal

BMC medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Ferreira JP, Mehta C, Sharma A, Nissen SE, Rossignol P, Zannad F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32493335

Résumé

The EXAMINE trial tested the efficacy and safety of alogliptin, an inhibitor of dipeptidyl peptidase 4, compared with placebo in 5380 patients with type 2 diabetes and a recent acute coronary syndrome. Because alogliptin is cleared by the kidney, patients were stratified according to screening renal function within two independently randomized strata: (1) estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m and (2) eGFR < 60 ml/min/1.73m. We aim to assess the efficacy and safety of alogliptin vs. placebo according to the renal function strata.

Mots clés

Alogliptin, Outcomes, Renal function, Stratification

Référence

BMC Med. 2020 Jun 4;18(1):165